DM
HOWL icon

Deerfield Management’s Werewolf Therapeutics HOWL Stock Holding History

Deerfield Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-958,125
Closed -$4.32M – 111
2022
Q3 		$4.32M Hold
958,125
– – 0.09% 98
2022
Q2 		$3.92M Hold
958,125
– – 0.08% 98
2022
Q1 		$4.22M Hold
958,125
– – 0.09% 89
2021
Q4 		$11.4M Sell
958,125
-794,662
-45% -$12M 0.24% 79
2021
Q3 		$30.1M Sell
1,752,787
-800,000
-31% -$13.7M 0.59% 49
2021
Q2 		$44.5M Buy
+2,552,787
New +$35M 0.79% 43

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Deerfield Management's HOWL Position: Q4 2022 in Review

Deerfield Management sold out of Werewolf Therapeutics (HOWL) in Q4 2022, closing a stake of 958,125 shares — an estimated $4.32M sold.

Deerfield Management first reported a position in HOWL in Q2 2021 and held it in 6 quarters. The position peaked at $44.5M in Q2 2021. 39 funds tracked by Wall St. Rank hold HOWL as of Q4 2022.

  • Deerfield Management reported no remaining Werewolf Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Deerfield Management sold 958,125 Werewolf Therapeutics shares in Q4 2022, an estimated $4.32M.
  • Deerfield Management first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 6 quarters.
  • Deerfield Management's Werewolf Therapeutics position peaked at $44.5M in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2022.

Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.